Skip to content

    Lung Disease & Respiratory Health Center

    Font Size
    A
    A
    A

    Viagra Ingredient OK'd for Lung Problem

    Revatio Cleared to Treat Pulmonary Hypertension
    By
    WebMD Health News

    June 8, 2005 -- The FDA has approved Viagra's active ingredient to treat pulmonary hypertension, a rare, life-shortening lung disorder that causes high blood pressure in the lungs.

    Viagra's maker, Pfizer, a WebMD sponsor, announced the approval in a news release. Pfizer will repackage Viagra's key ingredient (sildenafil) and market it as Revatio.

    Revatio would be used to improve exercise ability in patients with pulmonary hypertension, says Pfizer. The approved dose is limited to 20 milligrams three times daily. The white, round pills will look different from Viagra's blue diamonds and should be available by mid-July, says Pfizer.

    Rare Condition

    Pulmonary hypertension involves dangerously high pressure in the blood vessels that lead from the heart to the lungs. It affects an estimated 100,000 people worldwide, says Pfizer.

    Most cases of pulmonary hypertension are due to some underlying condition, such as chronic lung or heart disease. Nearly 300 cases, mostly women in their 30s, are diagnosed per year, says the National Heart, Lung, and Blood Institute (NHLBI). There is no known cause.

    Symptoms include difficulty breathing, dizziness, and fatigue. Without treatment, patients live less than three years from the time of diagnosis, on average, says Pfizer.

    Another oral drug, Tracleer, is also used to treat the condition. Revatio's effectiveness hasn't been evaluated in patients taking Tracleer, says Pfizer. The drug company says Revatio is the first oral treatment approved for patients with an early stage of the progressive condition.

    Study's Results

    The FDA's approval was based on a study of 277 people with pulmonary hypertension, says Pfizer. Patients were randomly assigned to get a placebo or 20, 40, or 80 milligrams of Revatio three times daily.

    After 12 weeks, all three Revatio groups showed "highly significant improvements" in the distance they could walk in six minutes, compared with the placebo group, says Pfizer. Average pressure in the lung arteries and other heart functions also improved with Revatio, and in a year-long trial, 94% of patients taking Revatio were still alive, says Pfizer.

    No particular dose had an advantage, and the lowest dose was approved.

    Today on WebMD

    man coughing
    You may not even know you have it.
    blood clot
    Signs of this potentially fatal complication.
     
    man coughing
    When a cold becomes bronchitis.
    human lungs
    Causes behind painful breathing, fluid buildup.
     

    chest x-ray
    Slideshow
    Bronchitis Overview
    SLIDESHOW
     
    Copd Myth Fact Quiz
    QUIZ
    Energy Boosting Foods
    SLIDESHOW
     

    lungs
    Article
    smokestacks
    Article
     
    woman coughing
    Article
    Lung xray and caduceus
    Article